Immunotherapy in Breast Cancer: the New Frontier

PURPOSE OF REVIEW: This review summarizes current immunotherapies in breast cancer, with an emphasis on immune checkpoint inhibitors and vaccines. RECENT FINDINGS: Combination immunotherapy with checkpoint inhibitors and cytotoxic therapies have shown promising results. Active clinical trials are on...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Zishuo I., McArthur, Heather L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Translational Research (RL Aft, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970253/
https://www.ncbi.nlm.nih.gov/pubmed/29881518
http://dx.doi.org/10.1007/s12609-018-0274-y
_version_ 1783326087313358848
author Hu, Zishuo I.
McArthur, Heather L.
author_facet Hu, Zishuo I.
McArthur, Heather L.
author_sort Hu, Zishuo I.
collection PubMed
description PURPOSE OF REVIEW: This review summarizes current immunotherapies in breast cancer, with an emphasis on immune checkpoint inhibitors and vaccines. RECENT FINDINGS: Combination immunotherapy with checkpoint inhibitors and cytotoxic therapies have shown promising results. Active clinical trials are ongoing in both early stage and metastatic settings for triple negative, HER2+, and hormone-positive breast cancer patients. SUMMARY: Ongoing challenges remain in defining biomarkers that predict response to immunotherapy, determining the optimal combination immunotherapies, and enhancing the immunogenicity of breast cancer subtypes.
format Online
Article
Text
id pubmed-5970253
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-59702532018-06-05 Immunotherapy in Breast Cancer: the New Frontier Hu, Zishuo I. McArthur, Heather L. Curr Breast Cancer Rep Translational Research (RL Aft, Section Editor) PURPOSE OF REVIEW: This review summarizes current immunotherapies in breast cancer, with an emphasis on immune checkpoint inhibitors and vaccines. RECENT FINDINGS: Combination immunotherapy with checkpoint inhibitors and cytotoxic therapies have shown promising results. Active clinical trials are ongoing in both early stage and metastatic settings for triple negative, HER2+, and hormone-positive breast cancer patients. SUMMARY: Ongoing challenges remain in defining biomarkers that predict response to immunotherapy, determining the optimal combination immunotherapies, and enhancing the immunogenicity of breast cancer subtypes. Springer US 2018-04-16 2018 /pmc/articles/PMC5970253/ /pubmed/29881518 http://dx.doi.org/10.1007/s12609-018-0274-y Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Translational Research (RL Aft, Section Editor)
Hu, Zishuo I.
McArthur, Heather L.
Immunotherapy in Breast Cancer: the New Frontier
title Immunotherapy in Breast Cancer: the New Frontier
title_full Immunotherapy in Breast Cancer: the New Frontier
title_fullStr Immunotherapy in Breast Cancer: the New Frontier
title_full_unstemmed Immunotherapy in Breast Cancer: the New Frontier
title_short Immunotherapy in Breast Cancer: the New Frontier
title_sort immunotherapy in breast cancer: the new frontier
topic Translational Research (RL Aft, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970253/
https://www.ncbi.nlm.nih.gov/pubmed/29881518
http://dx.doi.org/10.1007/s12609-018-0274-y
work_keys_str_mv AT huzishuoi immunotherapyinbreastcancerthenewfrontier
AT mcarthurheatherl immunotherapyinbreastcancerthenewfrontier

Ejemplares similares